NCT05761704View on ClinicalTrials.gov

Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation

NARecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

November 16, 2024

Study Completion Date

May 16, 2025

Conditions
Non-valvular Atrial Fibrillation
Interventions
DRUG

Dual antiplatelet

Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).

DRUG

Novel oral anticoagulant

Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine at Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER